Fisher Asset Management
SAGE

Fisher Asset Management’s Sage Therapeutics SAGE Stock Holding History

Fisher Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-432,545
Closed -$3.12M – 1007
2024
Q3 		$3.12M Sell
432,545
-3,876
-0.9% -$35.5K ﹤0.01% 533
2024
Q2 		$4.74M Buy
436,421
+3,952
+0.9% +$50.6K ﹤0.01% 494
2024
Q1 		$8.1M Buy
432,469
+544
+0.1% +$12.5K ﹤0.01% 449
2023
Q4 		$9.36M Buy
431,925
+32,306
+8% +$640K ﹤0.01% 421
2023
Q3 		$8.22M Sell
399,619
-31,527
-7% -$911K ﹤0.01% 455
2023
Q2 		$20.3M Buy
431,146
+10,229
+2% +$509K 0.01% 371
2023
Q1 		$17.7M Sell
420,917
-17,659
-4% -$759K 0.01% 380
2022
Q4 		$16.7M Sell
438,576
-6,238
-1% -$238K 0.01% 374
2022
Q3 		$17.4M Buy
+444,814
New +$17.2M 0.01% 350

Other funds holding SAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Fisher Asset Management's SAGE Position: Q4 2024 in Review

Fisher Asset Management sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 432,545 shares — an estimated $3.12M sold.

Fisher Asset Management first reported a position in SAGE in Q3 2022 and held it in 9 quarters. The position peaked at $20.3M in Q2 2023. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Fisher Asset Management reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Fisher Asset Management sold 432,545 Sage Therapeutics shares in Q4 2024, an estimated $3.12M.
  • Fisher Asset Management first reported a position in Sage Therapeutics in Q3 2022 and held it in 9 quarters.
  • Fisher Asset Management's Sage Therapeutics position peaked at $20.3M in Q2 2023.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Fisher Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.